A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects With Early Alzheimer's Disease

Trial Profile

A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects With Early Alzheimer's Disease

Recruiting
Phase of Trial: Phase III

Latest Information Update: 08 Dec 2017

At a glance

  • Drugs Elenbecestat (Primary)
  • Indications Alzheimer's disease
  • Focus Therapeutic Use
  • Acronyms MissionAD2
  • Sponsors Eisai Co Ltd
  • Most Recent Events

    • 21 Nov 2017 Planned End Date changed from 1 Sep 2020 to 1 Dec 2020.
    • 21 Nov 2017 Planned primary completion date changed from 1 Aug 2020 to 1 Nov 2020.
    • 30 Oct 2017 According to an Eisai Inc media release, a poster regarding the use of the International Shopping List Test (ISLT) as an objective cognitive assessment to select individuals with early Alzheimer's disease in clinical trials, including this trial will be presented during the 10th annual Clinical Trials on Alzheimer's Disease (CTAD) meeting 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top